ReviewPulmonary circulation2022

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

Steven D Nathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.